Dishman Carbogen Amcis P/E Ratio
Dishman Carbogen Amcis P/E ratio. Dishman Carbogen Amcis (DCAL) P/E ratio is not applicable — EPS (TTM) ₹6.22, 1 consecutive loss quarter. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Consecutive Loss Quarters: 1
Current EPS: ₹6.22
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Sept 2026 | -4.26 | -67 | Loss |
| Mar 2026 | 1.39 | 22 | Profit |
| Jun 2026 | -3.69 | -58 | Loss |
| Sept 2025 | 4.16 | 65 | Profit |
| Mar 2025 | 2.75 | 43 | Profit |
| Jun 2025 | 1.49 | 23 | Profit |
| Dec 2025 | -0.83 | -13 | Loss |
| Sept 2024 | 2.11 | 33 | Profit |
Healthcare Peers with Valid P/E Ratios — DCAL Comparison
Healthcare sector average P/E 52.19, median 29.6 — DCAL excluded (negative EPS).
Sector Average PE
52.19
Sector Median PE
29.6
Lowest PE
2.0
Profitable Companies
256
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.0 | ₹72 | Low |
| Brooks Laboratories | BROOKS | 2.6 | ₹206 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.3 | ₹54 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.1 | ₹6,355 | Low |
| Dipna Pharmachem | DPL | 4.5 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.7 | ₹82 | Low |
| Royal Sense | ROYAL | 4.8 | ₹34 | Low |
| Star Imaging And Path Lab | STARIMAGIN | 5.3 | ₹110 | Low |
| Kabra Drugs | KABRADG | 6.3 | ₹49 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see DCAL share price.
- Check Dishman Carbogen Amcis market worth to track the company's total market size over time.
- Also explore Dishman Carbogen Amcis stock price data download to track price trends across different timeframes.